Flosteron (Betamethasone) [Diprospan] suspension for injection
22763USD

Flosteron (Betamethasone) [Diprospan] suspension for injection

SKU:2485
To favorites
Flosteron (Betamethasone) [Diprospan] suspension for injection has anti-inflammatory, anti-allergic, desensitizing, anti-shock, anti-toxic and immunosuppressive effects, inhibits the release of adrenocorticotropic hormone by the pituitary gland
Active substance:Betamethasone
Pharmacological group:anti-inflammatory
Formulation:ampoules
Country of origin:Slovenia
In stock
$27
11
Description
Features
Reviews

Instructions for Flosteron (Betamethasone) [Diprospan] suspension for injection

English product name
Flosteron

Release Form
Injection suspension

Description Diprospan

Injection suspension 1 ml
betamethasone dinatria phosphate 2 mg
betamethasone dipropionate 5 mg
1 ml - ampoules (5) - packages of contour plastic (1) - packs of cardboard.

ATC codes
H02AB01 Betamethasone

Clinical-pharmacological groups / Group affiliation
GCS for injection - combination of depo-form and fast form

Active substance
betamethasone dinatria phosphate
betamethasone dipropionate

Pharmaco-therapeutic group Diprospan

Glucocorticosteroid

Storage Conditions
Store the drug in a place protected from light, at a temperature not higher than 25 ° C. Store in a place not accessible to children.

Best before date
The shelf life is three years.
Do not use the drug after the expiry date.

Pharmacological effect Diprospan

Betamethasone is a synthetic GCS that inhibits the release of interleukin-1, interleukin-2, gamma interferon from lymphocytes and macrophages. It has anti-inflammatory, anti-allergic, desensitizing, anti-shock, anti-toxic and immuno-depressive effects. It suppresses the release of pituitary ACTH and beta-lipotropin, but does not reduce the level of circulating beta-endorphin. Inhibits the secretion of thyroid hormone (TGT) and follichul-stimulating hormone (FSH).

Testimony Diprospan

  • Local treatment:
  • Intrauterine and perioarticular administration in inflammatory rheumatic diseases (rheumatoid arthritis, seronegative
  • spondyloarthritis, arthritis in systemic connective tissue diseases), in post-traumatic arthritis, in psoriatic arthritis with multiple
  • joint lesions and tendosinitis, in crystalline arthritis;
  • intrauterine administration in degenerative rheumatic diseases, especially in the presence of synovitis (not used in hip arthrosis);
  • inflammatory lesions of parotid tissues (bursitis, tendonitis, tendosinovite, epicondylitis, plantar fasciitis);
  • introduction to the lesion site for the treatment of skin diseases in rare cases (if there is no reaction to other methods of local
  • therapy): sclerosing folliculitis, keloids, ring granulema, skin sarcoidosis, diabetic lipodystrophy (liponecrosis), psoriasis, focal
  • alopecia, flat red lichai, neurodermite, monoid eczema, disc red lupus.
  • Systemic treatment:

systemic Flosterone effect is used in some pronounced allergic diseases: allergic rhinitis, asthmatic status, Quincke edema, allergic reactions to drugs and serums, insect bites.


Method of use, course and dosage Diprospan

The route of administration is parenteral (intra-articular, near-articular, intra-skin administration, administration to the affected tissue area and, in exceptional situations, in/m administration).

The dose for adults and children should be determined individually, depending on the size of the joint, severity, nature of the disease and the patient's reaction.
Intra-articular and near-articular introduction:
very large joints (hip) - one - two ml;
large joints (wheeled, shoulder, ankle) - one ml;
Medium size joints (elbow, wrist) - 0.5-1 ml;
Small joints (pectoral and clavicle, five phalanges, interphalanges) - 0.25-0.5 ml. For acute podagric arthritis, 0.5 to 1 ml is used.

  • Nosology (ICD codes)
  • J30.1
  • Allergic rhinitis caused by plant pollen
  • J30.3
  • Other allergic rhinitis (year-round allergic rhinitis)
  • J46
  • Asthmatic status [status asthmaticus]
  • L20.8
  • Other atopic dermatitis (neurodermatitis, eczema)
  • L28.0
  • Simple chronic lychee (limited neurodermatitis)
  • L30.0
  • Monetoid eczema
  • L40
  • Psoriasis
  • L43
  • Lishay red flat
  • L63
  • Palatal alopecia
  • L91.0
  • Hypertrophic scar
  • L93.0
  • Red lupus erythematosus
  • L94.0
  • Localized scleroderma [morphea]
  • M05
  • Seropositive rheumatoid arthritis
  • M07
  • Psoriatic and enteropathic arthropathy
  • M10
  • Podagra
  • M15
  • Polyarthrosis
  • M65
  • Synovitis and tenosinovites
  • M70
  • Soft tissue diseases related to load, overload and pressure
  • M71
  • Other bursopathy
  • M72
  • Fibroplastic abnormalities
  • M77
  • Other Entesopathy (epicondylitis)
  • M79.0
  • Rheumatism unspecified
  • T78.3
  • Angioneurotic edema (Quincke edema)
  • T88.7
  • Pathological reaction to a drug or medicines unspecified
Features
Active substance
Pharmacological group
Formulation
Country of origin
Expiration Date
No reviews yet — your comment may be first.
All reviews 0
general rating
Also buying with this item